As this novel parameter was designed for a substitute to conventional parameters representing prostate oncological hazards, our performance analysis included two functions of conventional clinical PSA measurement: detection of the presence of prostate cancer in screening and definition of the oncological status of prostate cancer patients before definitive treatment. This evidence concerns the gene KLK3 and Familial prostate cancer.